Kymera Therapeutics Announces Positive Phase 1 Study Results

Kymera Therapeutics ( (KYMR) ) just unveiled an announcement.

On June 2, 2025, Kymera Therapeutics announced positive results from their Phase 1 healthy volunteer study of KT-621, an oral STAT6 degrader aimed at treating immuno-inflammatory diseases. The study demonstrated robust STAT6 degradation in blood and skin, with a favorable safety profile comparable to placebo, and showed potential for KT-621 to be a transformative treatment for Th2 diseases. The company plans to advance KT-621 into Phase 1b and Phase 2b trials for atopic dermatitis and asthma, respectively, in late 2025 and early 2026.

The most recent analyst rating on (KYMR) stock is a Buy with a $46.00 price target. To see the full list of analyst forecasts on Kymera Therapeutics stock, see the KYMR Stock Forecast page.

Spark’s Take on KYMR Stock

According to Spark, TipRanks’ AI Analyst, KYMR is a Neutral.

Kymera Therapeutics shows a blend of strengths and challenges typical of a biotech firm. Strong equity and strategic pipeline advancements are offset by declining revenue and cash flow difficulties. Technical signals are mixed, and the valuation is unattractive due to negative earnings. The overall score reflects these mixed indicators, with positive guidance from the earnings call providing some optimism.

To see Spark’s full report on KYMR stock, click here.

More about Kymera Therapeutics

Kymera Therapeutics is a clinical-stage biotechnology company focused on developing oral small molecule degrader medicines targeting immunological diseases.

Average Trading Volume: 717,224

Technical Sentiment Signal: Sell

Current Market Cap: $1.93B

For an in-depth examination of KYMR stock, go to TipRanks’ Stock Analysis page.